Matter, a Chicago-based healthcare technology incubator and innovation hub, has joined forces with Three Lakes Partners in a $1 million innovation challenge to crowdsource ideas to improve the quality of life for idiopathic pulmonary fibrosis patients and their caregivers, according to a press release.
The IPF Catalyst Challenge is also intended to bring greater awareness to this disease, noted Steven Collens, Matter CEO. The competition was launched as part of a two-day IPF symposium convened at Matter. The challenge also marks a milestone for the incubator as the largest healthcare prize it has offered to date.
Why Your Patients Are Leaving and How to Stop It
Patient expectations continue to evolve, and healthcare practices that fail to adapt risk more than just revenue—they risk losing trust.
The incurable lung disease attacks lung tissue, scarring and stiffening it. This hinders the lungs’ ability to transport oxygen into the bloodstream, making it tough to breathe. People with the condition succumb to the disease within 5 years of the diagnosis. Approximately 125,000 people live with the condition in the U.S., and about 40,000 die each year from the disease.
So what kinds of submissions do the organizers hope the competition will generate?
- Smarter solutions for oxygen therapy;
- Patient and caregiver management apps and tools;
- Patient education;
- Devices and diagnostics; and
- Ways to find a cure for IPF.
The competition is looking for submissions from entrepreneurs and innovators spanning technology, healthcare, and scientific research communities
Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
Design consultancy IDEO and Common Pool, which specializes in crowdsourcing ideas for challenging problems, are also supporting the IPF Catalyst Challenge.
“Our mission is on behalf of patients and caregivers: to increase visibility of this disease and to attack IPF from all sides — diagnosis, treatment, and patient quality of life — all by engaging the most innovative, aggressive, and experienced partners in our collective fight,” said Ken Bahk, Three Lakes Partners managing director in the statement.
Photo: lvcandy, Getty Images